Hansa Biopharma AB: Valuation, Funding & Investors
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Hansa's portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy that facilitates kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with potential for redosing. Based in Lund, Sweden, Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $131M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $60M
- Latest Funding Round
- Investment
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Investment | $60.00M | ― |
| Oct 08, 2025 | Investment | $71.30M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Polar Capital LLP | Investment |
| Redmile Group | Investment |
Similar Companies
A snapshot of private companies similar to Hansa Biopharma AB, helping you discover and navigate related company profiles.








